Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.48 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4332341 | 0.74 | CALM1 (0.51) | ALOX5CALM1ALDH1A1F2RL1POLB | |
| SCHEMBL1134521 | 0.72 | PPARG (0.52) | KMT2AALDH1A1 | |
| SCHEMBL1134596 | 0.72 | F2RL1 (0.42) | ALOX5CALM1KMT2AALDH1A1F2RL1 | |
| SCHEMBL3777215 | 0.70 | LDHA (0.46) | ALDH1A1F2RL1CYP2D6HTTPOLB | |
| Trifluoroacetic Acid SCHEMBL4313499 | 0.70 | KDM4E (0.47) | ALOX5CALM1 | |
| SCHEMBL8336704 | 0.70 | ALOX5 (0.44) | ALOX5CALM1ALDH1A1F2RL1POLB | |
| SCHEMBL9864987 | 0.70 | LDHA (0.51) | ALOX5CALM1KMT2AALDH1A1F2RL1 | |
| SCHEMBL659052 | 0.69 | ALOX5 (0.68) | ALOX5CALM1KMT2AALDH1A1F2RL1 | |
| SCHEMBL4324683 | 0.69 | ALOX5 (0.43) | ALOX5CALM1KMT2AALDH1A1AOC3 | |
| SCHEMBL4313541 | 0.69 | ALOX5 (0.43) | ALOX5CALM1KMT2AALDH1A1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664228-B2 | 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of airway diseases | NOVARTIS AG (CH) | 2014-03-04 | — | — | US | disclosed |
| EP-2285785-B1 | 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF ARWAY DISEASES | NOVARTIS AG (CH) | 2012-09-05 | — | — | EP | disclosed |
| US-20110059989-A1 | 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF AIRWAY DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | US | disclosed |
| EP-2285785-A1 | 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF ARWAY DISEASES | Novartis AG (CH) | 2011-02-23 | — | — | EP | disclosed |
| WO-2009138378-A1 | 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF ARWAY DISEASES | NOVARTIS AG (CH) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059989-A1 | 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF AIRWAY DISEASES | CFTR, SCN5A, SCNN1B | ALOX5 1025/4885CALM1 716/4885KMT2A 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.